Show simple item record

dc.contributor.authorMelosky, B
dc.contributor.authorPopat, S
dc.contributor.authorGandara, DR
dc.date.accessioned2018-02-14T09:55:29Z
dc.date.issued2018-01
dc.identifier.citationClinical lung cancer, 2018, 19 (1), pp. 42 - 50
dc.identifier.issn1525-7304
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1062
dc.identifier.eissn1938-0690
dc.identifier.doi10.1016/j.cllc.2017.05.019
dc.description.abstractThe optimal treatment sequence for patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive (EGFR-M + ) non-small-cell lung cancer (NSCLC) continues to evolve, related largely to an increasing number of breakthroughs and studies in the field. The efficacy of tyrosine kinase inhibitors in the treatment of these patients is well established; however, the treatment decision-making process is becoming more complex as our knowledge of EGFR mutations and resistance pathways grows and more treatment options become available. Thus, treating physicians must consider an increasing number of factors. We present a stepwise approach to personalizing the treatment of patients with EGFR-M + NSCLC, emphasizing some of the real world challenges faced by treating physicians. We reviewed the decision criteria for selecting the best first-line therapy, highlighted the importance of repeat biopsy on disease progression to determine the most appropriate next-line therapy, and discussed the options for third-line therapy and beyond. We also present an algorithm designed to optimize the sequencing strategies for prolonging survival and maintaining quality of life in our patients with EGFR-M + NSCLC.
dc.formatPrint-Electronic
dc.format.extent42 - 50
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectCarcinoma, Non-Small-Cell Lung
dc.subjectLung Neoplasms
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectProtein Kinase Inhibitors
dc.subjectTreatment Outcome
dc.subjectSurvival Analysis
dc.subjectDrug Resistance
dc.subjectMutation
dc.subjectAlgorithms
dc.subjectPatient Selection
dc.subjectQuality of Life
dc.subjectRandomized Controlled Trials as Topic
dc.subjectCarcinogenesis
dc.subjectErbB Receptors
dc.subjectPrecision Medicine
dc.subjectGefitinib
dc.subjectAfatinib
dc.titleAn Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach.
dc.typeJournal Article
dcterms.dateAccepted2017-05-30
rioxxterms.versionofrecord10.1016/j.cllc.2017.05.019
rioxxterms.licenseref.startdate2018-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfClinical lung cancer
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume19
pubs.embargo.termsNot known
icr.researchteamThoracic Oncologyen_US
dc.contributor.icrauthorPopat, Sanjayen
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record